We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

QUIDEL

Develops, manufactures and markets rapid diagnostic tests at the point-ofcare (POC) that focus on infectious diseases... read more Featured Products: More products

Download Mobile App





Ortho Presents Broad Menu of High-Performing Assays at EUROMEDLAB 2022

By LabMedica International staff writers
Posted on 11 Apr 2022
Print article
Image: Ortho’s assays are optimized to meet changing testing needs (Photo courtesy of Ortho Clinical Diagnostics)
Image: Ortho’s assays are optimized to meet changing testing needs (Photo courtesy of Ortho Clinical Diagnostics)

Ortho Clinical Diagnostics (Raritan, NJ, USA) presented its comprehensive, fully integrated and completely scalable solutions, including its broad menu of high-performing assays, at EUROMEDLAB 2022.

Ortho presented its VITROS Dashboards, a web-based system designed to provide productivity information regarding analyzers, test volumes, workload balance, HIT (Hemolysis, Icterus, Turbidity) levels, and reagent efficiency. The highlight of Ortho’s presentation at EUROMEDLAB 2022 was its VITROS COVID-19 Performance Dashboard - a web-based system designed to provide productivity information regarding Ortho analyzers, including volumes, workload balance, HIT levels, and reagent efficiency for each site within the health system. The VITROS COVID-19 Performance Dashboard is located within the Ortho Plus environment and is an extension of Ortho’s e-Connectivity Technology. e-Connectivity not only supports the delivery of timely and accurate results to patients and physicians, it also protects patient data.

With the ability to monitor antibody testing trends, users can adjust staffing and workflow according to their testing volumes. Labs can quantify the number of samples processed the first time - even when HIT interference is present, giving them the ability to spot negative trends in order to take action. With the VITROS COVID-19 Performance Dashboard, users have access to data that will give them a better understanding of the virus, including its impact on their lab and hospital, to adjust accordingly. With signal to cut off values, labs can see the separation between positive and negative results, giving them confidence in their results. The VITROS COVID-19 Performance Dashboard assisting users in their quest to improve laboratory efficiency and decision support while providing the best care for their patients and staff.

IN Addition, Ortho demonstrated how laboratories can contribute to patient blood management initiatives by minimizing impact of common interferences amongst other challenges. The company also exhibited its broad menu of high-performing assays that are optimized to meet the changing testing needs of laboratories.

Related Links:
Ortho Clinical Diagnostics 

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Dengue Virus Test
LINEAR Dengue-CHIK

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more

Molecular Diagnostics

view channel
Image: Researchers have found the first evidence of testing for the alpha-synuclein protein in blood samples via seed amplification assay (Photo courtesy of Shutterstock)

Blood Test to Detect Alpha-Synuclein Protein Could Revolutionize Parkinson's Disease Diagnostics

Currently, Parkinson's disease (PD) is identified through clinical diagnosis, typically at a later stage in the disease's progression. There is a pressing need for an objective and quantifiable biomarker... Read more

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Immunology

view channel
Image: The blood test measures lymphocytes  to guide the use of multiple myeloma immunotherapy (Photo courtesy of 123RF)

Simple Blood Test Identifies Multiple Myeloma Patients Likely to Benefit from CAR-T Immunotherapy

Multiple myeloma, a type of blood cancer originating from plasma cells in the bone marrow, sees almost all patients experiencing a relapse at some stage. This means that the cancer returns even after initially... Read more

Microbiology

view channel
Image: Ultra-Rapid Antimicrobial Susceptibility Testing (uRAST) revolutionizing traditional antibiotic susceptibility testing (Photo courtesy of Seoul National University)

Ultra-Rapid Culture-Free Sepsis Test Reduces Testing Time from Days to Hours

Sepsis, a critical emergency condition, results from an overactive inflammatory response to pathogens like bacteria or fungi in the blood, leading to organ damage and the possibility of sudden death.... Read more

Pathology

view channel
Image: The AI model can distinguish different stages of DCIS from inexpensive and readily available breast tissue images (Photo courtesy of David A. Litman/Shutterstock)

AI Model Identifies Breast Tumor Stages Likely To Progress to Invasive Cancer

Ductal carcinoma in situ (DCIS) is a non-invasive type of tumor that can sometimes progress to a more lethal form of breast cancer and represents about 25% of all breast cancer cases. Between 30% and 50%... Read more

Industry

view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.